• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Gelteq Limited

    3/24/26 8:15:06 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GELS alert in real time by email
    6-K 1 ea0282795-6k_gelteq.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2026

     

    Commission File Number: 001-42373

     

    Gelteq Limited

    (Registrant’s Name)

     

    Level 19

    644 Chapel Street

    South Yarra VIC, 3141
    Australia

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒   Form 40-F ☐

     

     

     

     

     

    INFORMATION CONTAINED IN THIS FORM 6-K REPORT 

     

    On March 18, 2026, Gelteq Limited (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price per share for its ordinary shares, no par value, (“Ordinary Shares”) was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company’s Ordinary Shares, and the shares will continue to trade uninterrupted under the symbol “GELS.”

     

    Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of one hundred eighty (180) calendar days, or until September 14, 2026 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company’s Ordinary Shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

     

    In the event the Company does not regain compliance by September 14, 2026, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Gelteq Limited
         
      By: /s/ Nathan Givoni
      Name: Nathan Givoni
      Title: Chief Executive Officer

     

    Date: March 24, 2026

     

     

    2

     

     

    Get the next $GELS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GELS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GELS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wynne Paul Michael

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 8:17:20 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Szewach Simon H

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 8:16:29 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Karp Bradley Glenn

    3 - Gelteq Ltd (0001920092) (Issuer)

    3/18/26 7:18:40 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership

    MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq") and Healthy Extracts™ Inc. ("Healthy Extracts") today announced the signing of a Memorandum of Understanding ("MoU") formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution. Under the MoU, Healthy Extracts will leverage its established US-based nutritional manufacturing cap

    2/11/26 8:45:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform

    MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol ("CBD") compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients. Despite having

    1/13/26 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program

    MELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq's advanced hydration and sports performance formulations into the training and competition programs of the region's men's, women's, and youth national teams. The initiative underscores the increasing interest in high-performance programs throughout the region and builds on the recently announced China-focused sales agreement with Shenzhen Mana Health Management Co. Ltd., which includes minimu

    12/16/25 9:05:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    SEC Filings

    View All

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    3/24/26 8:15:06 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    12/9/25 3:19:42 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 20-F filed by Gelteq Limited

    NT 20-F - Gelteq Ltd (0001920092) (Filer)

    11/3/25 5:00:53 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Leadership Updates

    Live Leadership Updates

    View All

    Gelteq Appoints Matthew Jones as Head of Sports Performance

    NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie

    1/24/25 8:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO").  Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped

    12/19/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.   Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper

    11/12/24 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Financials

    Live finance-specific insights

    View All

    Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

    NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n

    12/2/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care